

ASX ANNOUNCEMENT

25 October 2022

Notice of change in auditor



Little Green Pharma Ltd (ASX: LGP, "**LGP**" or the "**Company**") announces that BDO Audit (WA) Pty Ltd ("**BDO**") has been appointed as the Company's auditors with effect from today, Tuesday 25 October 2022. This appointment follows the resignation of Deloitte Touche Tohmatsu ("**Deloitte**") and receipt of ASIC's consent to the same.

The Board's decision to change auditors followed a consultation process, with LGP selecting BDO given their reputation and experience with similarly sized companies to LGP.

In accordance with section 327(c) of the Corporations Act 2001, a resolution will be tabled at the Company's Annual General Meeting in 2023 to ratify the appointment of BDO as the Company's auditors.

LGP would like to take this opportunity to thank Deloitte for their assistance and services to the Company over the past 5 years.

ENDS

BY ORDER OF THE BOARD

A handwritten signature in black ink, appearing to be "Alistair Warren".

Alistair Warren
Company Secretary

For further information please contact:

Alistair Warren
Company Secretary
Little Green Pharma
E: a.warren@lgp.global
T: +61 8 6280 0050

Fleta Solomon
Chief Executive Officer
Little Green Pharma
E: f.solomon@lgp.global
T: +61 8 6280 0050



About Little Green Pharma

Little Green Pharma is a global, vertically integrated and geographically diverse medicinal cannabis business with operations from cultivation and production through to manufacturing and distribution.

The Company has two global production sites for the manufacture of its own-branded and white-label ranges of GMP-grade medicinal cannabis products, being a 21,500m² cultivation and 4,000m² GMP manufacturing facility capable of producing over 30 tonnes of medicinal cannabis biomass per annum located in Denmark (EU) and an indoor cultivation and manufacturing facility located in Western Australia capable of producing ~3 tonnes of medicinal cannabis biomass per annum.

Little Green Pharma products comply with all required Danish Medicines Agency and Therapeutic Goods Administration regulations and testing requirements. With a growing range of products containing differing ratios of active ingredients, Little Green Pharma supplies medical-grade cannabis products to Australian, European and overseas markets.

The Company has a strong focus on patient access in the emerging global medicinal cannabis market and is actively engaged in promoting education and outreach programs, as well as participating in clinical investigations and research projects to develop innovative new delivery systems.

For more information about Little Green Pharma go to: www.littlegreenpharma.com

Help us be Green

LGP investors are encouraged to go paperless and receive Company communications, notices and reports by email. This will ensure efficient communication during COVID-19 while also helping to reduce our costs and environmental footprint.

To easily update your communication preferences, visit: www.computershare.com.au/easyupdate/lgp